secwatch.observer — SEC 8-K summary
======================================

Issuer:     NextCure, Inc. (NXTC)
CIK:        0001661059
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001558370-24-014866
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NextCure Q3 net loss $11.5M, cash $75.3M; plans LNCB74 IND by Q4 2024
---------------------------------------------------------------------

- Net loss of $11.5M for Q3 2024, vs $14.3M in Q3 2023; R&D expense down to $8.8M.
- Cash, cash equivalents, and marketable securities $75.3M as of Sep 30, 2024; expected runway into H2 2026.
- LNCB74 (B7-H4 ADC) IND planned by Q4 2024; preclinical data at SITC in November.
- NC410 combo trial concluding, seeking partner; ovarian ICI-naïve response rate 25% (5/20) and CRC MSS 8.3% (3/36) PRs at 100 mg.
- Preclinical NC181 (Alzheimer's) and NC605 (osteogenesis) also seeking partner or financing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661059/000155837024014866/0001558370-24-014866-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661059/000155837024014866/nxtc-20241107x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-014866

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer